National Headlines

PRECISION MEDICINE: Human Longevity, Merck KGaA Form Cancer Biomarker Partnership

Jun 15, 2017 | Staff Reporter

NEW YORK (GenomeWeb) – Human Longevity (HLI) announced today that it has partnered with Germany’s Merck KGaA to identify treatment-response biomarker signatures in patients with advanced melanoma. In a pilot project, the companies will look for these biomarkers in patients with locally advanced or metastatic NRAS-mutated cutaneous melanoma who preferentially respond to Merck’s MEK1/2 inhibitor pimasertib. As part of the effort, HLI said it will generate genomic sequencing data from clinical trial participants’ tumors and germline DNA, then use its machine learning and analytical technologies to analyze the data in the context of survival and other clinical data.

eye #fordoctors concierge medicine dpc

READ FULL STORY …

SOURCE: https://www.genomeweb.com/cancer/human-longevity-merck-kgaa-form-cancer-biomarker-partnership

Advertisements

Categories: National Headlines

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s